Logo

Longbio Pharma Highlights Results from the P-I Study of LP-003 for Treating Chronic Spontaneous Urticaria at AAD 2024

Share this
Longbio Pharma

Longbio Pharma Highlights Results from the P-I Study of LP-003 for Treating Chronic Spontaneous Urticaria at AAD 2024

Shots:

  • The P-I trial assessed safety & PK/PD (free IgE levels) of LP-003 in healthy individuals (n=32) divided into 5 arms to administer single IV dosing (0.3mg/kg, 1mg/kg, 3mg/kg, 6mg/kg & 10 mg/kg)
  • The study depicted LP-003’s non-linear PK profile with a half-life of 44.6 to 76.5 days which was ~2-3 times that of omalizumab with a free-IgE suppression in the 1mg/kg (except for one participant with a high baseline IgE level) to 10mg/kg groups below the detection range for >168 days
  • The company is recruiting refractory CSU patients (n=200), symptomatic after anti-histamine (H1) treatment, for P-II study who will be divided into 5 arms (n=40/arm) incl. 3 LP-003 arms, 1 omalizumab arm & 1 PBO arm. Topline data is expected in early 2025

Ref: PR Newswire | Image: Longbio Pharma

Related News:- Sanofi Highlights Results from the P-II Trial of Rilzabrutinib for the Treatement of Chronic Spontaneous Urticaria (CSU) at AAAAI 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions